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dKey concepts
n New tools are available to aid vaccine manufacturers in meeting challenges for new vaccine development
, Many technologies that are already available continue to be improved, including adjuvants and novel vaccine
delivery platforms
, New methods are yet to be fully exploited, including reverse engineering (going from pathogen gene
sequences to immunogenic epitopes), screening of peptide libraries, and methods to increase antigen purity,
cross-protection and thermostability
n Persistent, highly variable and/or novel pathogens, and complex (eg polymicrobial) infections present challenges
to vaccine designers. Targets include new prophylactic vaccines that prevent the emergence of disease and new
therapeutic vaccines which augment or redirect the existing immune response to control persistent infections,
malignancies, autoimmune diseases and addiction
n State-of-the-art technology combined with a more comprehensive understanding of disease aetiology, pathogen
biology and host immunity will assist future vaccine developments to combat elusive pathogens and protect
populations with special needs2011 Elsevier B.V.
oi:10.1016/j.pervac.2011.05.006
Open access under CC BY-NC-ND license.
152 UNDERSTANDING MODERN VACCINESIntroduction
The advances made in vaccine technology since Edward Jenner
vaccinated the young James Phipps against smallpox have had
a spectacular impact on human health over the last two centuries (see
Chapter 1 e Vaccine evolution). Vaccines have been fundamental
in the control and elimination of many debilitating and lethal diseases,
and more diseases are currently targeted for eradication by
vaccination. Recent major breakthroughs in immunology, molecular
biology, genomics, proteomics, biochemistry and computing
sciences have driven vaccine technology forward, and will continue
to do so.
Many challenges remain, however, including persistent or latent
infections, pathogens with complex life cycles, antigenic drift and
shift in pathogens subject to selective pressures, challenging
populations and emerging infections. To address these challenges
researchers are exploring many avenues: novel adjuvants are being
developed that enhance the immune response elicited by a vaccine
while maintaining high levels of tolerability; methods of protective
antigen identiﬁcation are iterated with every success; vaccine
storage and transport systems are improving (including optimising
the cold chain and developing temperature-stable vaccines);
and new and potentially more convenient methods of vaccine
administration are being pursued.
High priority targets include life-threatening diseases, such as
malaria, tuberculosis (TB) and human immunodeﬁciency virus
(HIV), as well as problematic infections caused by ubiquitous
agents, such as respiratory syncytial virus (RSV), cytomegalovirus
(CMV) and Staphylococcus aureus. Non-traditional vaccines are
also likely to become available for the management of addiction,
and the prevention, treatment and cure of malignancies.
This chapter is not meant as a compendium of all new-generation
vaccines, but rather as an outline of the modern principles that
will likely facilitate the development of future vaccines. As shown
in Figure 6.1, there are several key elements that are likely to be
Figure 6.1 Modern elements of vaccine development. Strategies to improve the prevention and/or treatment of diseases through the use of
vaccination are multifaceted. Methods include improved antigen identiﬁcation, puriﬁcation and presentation; use of new adjuvants; and more
targeted vaccine administration for use against elusive pathogens and in special populations.
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VACCINES OF THE FUTURE 153the foundation for the development of future vaccines. This
chapter will illustrate these elements and provide examples that
show promise.New adjuvants
ACHIEVEMENTS OF ADJUVANTS
Since the ﬁrst use of an adjuvant in a human vaccine over 80
years ago, adjuvant technology has improved signiﬁcantly with
respect to improving vaccine immunogenicity and efﬁcacy. Over
Figure 6.2 Roles of adjuvants in future vaccines. New and fu
various roles aimed at maximising vaccine efﬁcacy and durab
increase the impact of vaccination programmes.
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154 UNDERSTANDING MODERN VACCINES30 currently licensed vaccines have an adjuvant component in
their formulation (see Chapter 4 e Vaccine adjuvants; Figure 4.1).
The advances in adjuvant design have been driven by parallel
advances in vaccine technology as many modern vaccines
consist of highly puriﬁed antigens e with low non-speciﬁc
reactogenicity which require combination with adjuvants to
enhance the immune response. Future developments in adjuvant
technology are expected to provide stronger immune priming,
enhance immune responses in speciﬁc populations, and lead to
antigen sparing. Adjuvants to date have demonstrated an abilityture adjuvants (discussed in Chapter 4 e Vaccine adjuvants) will be employed to fulﬁl
ility, thus reducing the amount of antigen needed when in short supply in an effort to
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Examples of new adjuvants are the
nanoemulsions developed by NanoBio
Corporation. Nanoemulsions are
oil-in-water emulsions manufactured in
various sizes £400 nm and stabilised by
a surfactant. These technologies are
amenable to topical and mucosal
administration and can be used to
deliver antigens or used alone to
physically disrupt the outer membrane
of pathogenic organisms. When
administered as a vaccine, the
nanoemulsion enhances vaccine
antigen uptake by antigen-presenting
cells, which then carry the antigen to
the lymph nodes e the site of adaptive
immune response initiation.
Nanoemulsion vaccines administered
intranasally elicit both mucosal
immunity and a systemic
immune response.
VACCINES OF THE FUTURE 155to increase and broaden the immune response e examples
include MF59 or AS03 adjuvants used in various inﬂuenza
vaccines, and aluminium or AS04 used in human papillomavirus
(HPV) vaccines. The impact of new adjuvant technology on vaccine
efﬁcacy has been demonstrated in inﬂuenza vaccines and in
candidatemalaria vaccines currently undergoing clinical testing, and
has opened the door to antigen-speciﬁc immunotherapy for cancer.
THE ROLE OF ADJUVANTS IN FUTURE VACCINES
New adjuvants must aim to drive the immune response that is
associated with lifelong protection. New adjuvants and adjuvant
combinations will play many roles in future vaccines as illustrated in
Figure 6.2. Adjuvants will need to be individually selected for
speciﬁc vaccine targets in order to achieve the desired goal (ie
enhanced immunogenicity, induction of speciﬁc immune proﬁle
etc). To deliver this aim, some adjuvants will be mixed with free
antigens, while others will need to be covalently linked to the
antigenic moiety as part of a complex molecule.
Some examples of new adjuvants that have been evaluated in
humans or that are in clinical trials are listed in Table 6.1 (also see
Chapter 4 e Vaccine adjuvants).
NEW APPROACHES TO ANTIGEN SELECTION
AND STABILITY
Modern approaches to antigen design tend to eschew classical
trial and error techniques in favour of identifying the type of
pathogenic structures (ie antigens) that are most likely to be
important immunogens based on their structural signature or
physical location within the pathogen (Table 6.2) (see Chapter 3 e
Vaccine antigens).
NOVEL APPROACHES TO ANTIGEN IDENTIFICATION
AND PURIFICATION
The T or B cell immune responses to an antigen are targeted
to precise regions of the antigen (ie epitopes e either linear or
TABLE 6.1. ADJUVANTS CONTAINED IN VACCINES CURRENTLY IN DEVELOPMENT
Adjuvant name Description Route of
delivery
Current
vaccine
targets
Manufacturer
Early-stage development (Phase I)
NanoStat Nanoemulsion Intranasal Inﬂuenza
Hepatitis B*
NanoBio
Corporation
CpG TLR9 agonist Intramuscular Malaria Coley
LT Escherichia coli heat-labile toxin Intranasal TB Novartis
Montanide ISA720 Water-in-oil emulsion Intramuscular Malaria
Cancer
Seppic
Resiquimod TLR7/8 agonist Intramuscular Melanoma 3M
ISCOM (with
antigen included)
ISCOMATRIX
(without antigen)
Lipids, cholesterol, saponin in a cage-like structure Intramuscular Alzheimer’s
disease
CSL Behring
IC31 TLR9 agonist and targets antigen to APC Intramuscular Inﬂuenza Intercell
Mid-stage development (Phase II)
ISCOM (with
antigen included)
ISCOMATRIX
(without antigen)
Lipids, cholesterol, saponin in a cage-like structure Intramuscular Inﬂuenza
Melanoma
HCV
CSL Behring
Flagellin (conjugated
with antigen)
TLR5 agonist Intramuscular Inﬂuenza VaxInnate
IC31 TLR9 agonist and targets antigen to APC Intramuscular TB Intercell
MF59 Squalene-based oil-in-water emulsion Intramuscular CMV Novartis
AS01 Liposome, lipopolysaccharide derivative (MPL) and
saponin (QS21)
Intramuscular TB
HIV
GSK
Biologicals
Late-stage development (Phase III)
ISS TLR9 agonist Intramuscular HBV Dynavax
AS01 Liposome, lipopolysaccharide derivative (MPL) and
saponin (QS21)
Intramuscular Malaria GSK
Biologicals
AS03 a-tocopherol and squalene in an oil-in-water emulsion Intramuscular Inﬂuenza GSK
Biologicals
Continued on next page
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TABLE 6.1. ADJUVANTS CONTAINED IN VACCINES CURRENTLY IN DEVELOPMENT e CONTINUED
Adjuvant name Description Route of
delivery
Current
vaccine
targets
Manufacturer
AS04 Lipopolysaccharide derivative (MPL) and aluminium salt Intramuscular HSV GSK
Biologicals
AS15 Liposome, lipopolysaccharide derivative (MPL),
saponin (QS21) and TLR9 agonist (CpG)
Intramuscular Lung cancer
Melanoma
GSK
Biologicals
Montanide ISA51 Water-in-oil emulsion Intramuscular Cancer Seppic
MF59** Squalene-based oil-in-water emulsion Intramuscular Inﬂuenza Novartis
MPL Lipopolysaccharide derivative Subcutaneous Non-small-cell
lung cancer
Merck
*National Institutes of Health funding received for Phase I trials e FDA approval pending as of April 2010.
**MF59 adjuvanted inﬂuenza vaccines has been approved in the EU and not in the USA
TLR, Toll-like receptor; TB, tuberculosis; APC, antigen-presenting cell; HCV, hepatitis C virus; CMV, cytomegalovirus; MPL, monophosphoryl
lipid A; HIV, human immunodeﬁciency virus; HBV, hepatitis B virus; HSV, herpes simplex virus; FDA, Food and Drug Administration; EU, European
Union. Every effort has been made to verify the information in the above table. The information included is not meant to be exhaustive but is
intended to provide an overview of the subject matter.
TABLE 6.2. KEY AREAS OF MODERN VACCINE-RELATED ANTIGEN RESEARCH AND NEW APPROACHES TO
ANTIGEN DISCOVERY
l Reverse vaccinology
l Epitope mapping and poly-epitope vaccines
l Expression library immunisation
l High-throughput screening of peptides using human T-cell stimulation to identify T-cell antigens
l Antigen stabilisation
VACCINES OF THE FUTURE 157three-dimensional conformational structures; in the case of protein
antigens these are speciﬁc peptide epitopes). Historically, simple,
linear, synthetic peptide epitope vaccines have been poorly
immunogenic because they lack a speciﬁc conformation and are
easily degraded by a variety of extracellular and cell-surface
proteases that serve to limit epitope presentation to T cells and/or
result in destruction of the B-cell epitope. Peptide vaccines need to
158 UNDERSTANDING MODERN VACCINESsurvive this environment in order to participate in successful
major histocompatibility complex (MHC) class II presentation (see
Chapter 2 e Vaccine immunology).
Subunit and individual epitope vaccines need to be optimised to
ensure adequate immunogenicity. Novel strategies are being
developed and exploited in order to identify antigens recognised by
T and B cells, thus facilitating a more knowledge-based vaccine
design.One of themost commonways to identify these antigens is to
measure cellular proliferation (T or B cells) upon in vitro stimulation
with antigen. High-throughput screening assays of candidate
synthetic peptides that drive cellular proliferation help speed the rate
of antigen discovery.
Reverse vaccinology
Reverse vaccinology combines knowledge of the pathogen’s
genome sequence with known protein sequences via computer
analysis, to predict protein expression and post-translational
modiﬁcations and identify likely vaccine candidates (see Chapter
3 e Vaccine antigens; Figure 3.5).
The development of epitope-based vaccines is one example of
reverse vaccinology where computer software combines prediction
algorithms to suggest sequences similar to those for pathogenic
components. Epitope mapping, combined with the creation of more
stable poly-epitope vaccines, may lead to the successful translation
of this technology into products.
Poly-epitope vaccines and MHC restriction
MHC molecules exhibit widely varying binding speciﬁcities;
a vaccine expressing a single peptide antigen would therefore only
target a few MHC molecules and thus only be recognised by
the T cells of individuals carrying a speciﬁc MHC phenotype.
Poly-epitope technology could be used to generate a synthetic
protein carrying antigenic epitopes from multiple strains or
pathogens. This would overcome the MHC restriction and afford
protection in individuals carrying different MHC types.
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The screening of pathogen peptide libraries is another example of
new approaches to antigen discovery. Screening methods are used
to identify antigens that can stimulate CD4þ or CD8þ T cells, or
which bind to antibodies from humans known to have been infected
with the relevant pathogen. Where peptide screening uses
antibodies, an additional consideration is the synthesis of antigens
that contain the tertiary (folding/three-dimensional) structure of the
native immunogen, since vaccine efﬁcacy can be impacted by
inﬁdelities in the structure of the ﬁnal product. Incorrect protein
folding may result in a less immunogenic antigen or an antigen that
induces an immune response that differs from that of the native
immunogen. The mimicking of the three-dimensional structure of
the native immunogen is important during the synthesis of antigens
that are being used to target B-cell responses. Conversely, the
requirement for folding is reduced for T cells since T cells bind only
processed peptides, from degraded proteins. Likewise, DNA
expression libraries using the pathogen genomic DNA have been
screened using animal model systems to identify genes encoding
proteins that afford protection against infection or disease caused
by the pathogen.
One example is Genocea’s vaccine development programmes that
are built around a broad platform for the rapid discovery of T-cell
antigens. The process is explained in Figure 6.3. T-cell antigens,
speciﬁcally antigens that stimulate CD4þ and CD8þ T cells, are
critical to generating disease-speciﬁc cellular immune responses
and long-term T-cell memory.
ANTIGEN STABILITY
Stability of the ﬁnal product is another important consideration.
Adverse environmental conditions can result in degradation of the
vaccine, rendering it non-immunogenic. In order to maintain product
integrity many vaccines (particularly live vaccines) must be stored at
cold temperatures (4C). The maintenance of the vaccine at this
temperature from production site to distribution site, and medical
ofﬁce or clinic, is referred to as the ‘cold chain’. Maintaining the cold
Figure 6.3 Genocea’s T-cell antigen discovery technology. Genocea’s vaccine development programmes are built around a transformational
platform for the rapid discovery of T-cell antigens. T-cell antigens, speciﬁcally antigens that stimulate CD4þ and CD8þ T cells, are critical to
generating disease-speciﬁc cellular immune responses and long-term T-cell memory (Genocea website, 2011).
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Modifying vaccine formulations to
increase tolerance to temperature
ﬂuctuations is likely to increase the
shelf-life of the product and reduce
transport and wastage issues.
160 UNDERSTANDING MODERN VACCINESchain is much less of a challenge in resource-rich countries, but can
be a major barrier to vaccine implementation in resource-limited
areas. Ongoing research designed to increase our understanding
of vaccine degradation may address the problems associated
with cold chain management and lead to the development of
thermostable vaccines.
New approaches to antigen delivery
ISSUES AFFECTING ANTIGEN PRESENTATION
The level of antigen presentation which occurs with some current
vaccines may sometimes be insufﬁcient to drive long-lasting
immune responses of high quality (see Chapter 3 e Vaccine
antigens). This may be due to inadequate exposure of the antigen to
immature antigen-presenting cells (APCs) rapid or subimmunogenic
degradation or sequestration of antigens, or lack of immunogenicity
due to the physical presentation of the antigen. The discovery and
VACCINES OF THE FUTURE 161reﬁnement of new and varied options for antigen presentation is
expected to allow the design of vaccines to produce speciﬁc
immune proﬁles. Some of these technologies have been shown to
facilitate oral delivery to target mucosal immune responses and also
trigger both innate and adaptive immune systems, including T- and
B-cell effector and memory responses.VIRAL VECTOR VACCINES
Candidate viral vector vaccines utilise a non-pathogenic virus to
carry and subsequently induce expression of genes that produce
immunogenic foreign proteins at high levels in the host. These are
taken up by immature APCs, and have been shown to lead to
a robust, long-lasting immune response to the target antigen
(Figure 6.4). Viral vector vaccines, eg recombinant poxvirus
vaccines, can be administered mucosally to stimulate mucosal
immune responses. The attenuated modiﬁed vaccinia virus Ankara
(rMVA) vectors are showing promise as mucosal delivery vectors.
Pre-existing immunity to the viral vaccine vector is an impediment to
successful use of this approach. As ways to avoid anti-vector
immunity, viruses can be attenuated or inactivated, by deleting or
replacing pathogenic genes. Figure 6.4 demonstrates how viral
vaccine vectors are made. DNA expressing an immunogenic
transgene (the vaccine antigen) is inserted into the viral vector
genome for expression following administration into the recipient;
expression of the vaccine antigen can be boosted by using a variety
of DNA promoters. If the viral vector is no longer able to grow
and replicate, the virus is grown using a cell line (a so-called
complementing cell line) that has been engineered to produce the
missing viral product.
Often, viral genes are removed in an effort to reduce or eliminate the
pathogenicity of the vector and in some cases viral genes are
removed to make the vector itself less immunogenic; an anti-vector
immune response would greatly reduce the ability of the vector to
induce an antigen-speciﬁc response. Examples of viral vector
candidate vaccines in clinical development are listed in Table 6.3.
Figure 6.4 Viral vectors for vaccines. Viral vector vaccines exploit the natural ability of viruses to infect or otherwise enter (in the case of disabled
viral vectors) host cells, and then deliver pathogen-speciﬁc antigens. Antigen-encoding genes are isolated from the pathogen and inserted into the
viral vector genome. The viral vector can then be used as a factory for production of large quantities of pathogen antigen in vivo, following
introduction of the vector into the vaccine recipient, with the pathogen antigen then expressed on the surface of the infected/transduced host
cells or exported out of the producer cell.
MHC, major histocompatibility complex.
162 UNDERSTANDING MODERN VACCINESBACTERIAL VECTOR VACCINES
Non-pathogenic bacterial vectors have many features that make
them an attractive vaccine platform. Bacterial vectors can be
engineered for maximum safety (eg deletion of two or more genes
from the same metabolic pathway), and to express large numbers
of foreign antigens (Figure 6.5).
Two key issues affecting bacterial vaccine vectors are: a) to decide
whether the optimal platform should be a bacterial vaccine in its
TABLE 6.3. EXAMPLES OF VIRAL VECTOR CANDIDATE VACCINES IN VARIOUS STAGES OF CLINICAL
DEVELOPMENT
Vector Pathogen target Manufacturer
Early-stage development (Phase I)
Adenovirus HIV
Ebola-Marburg
HCV
Crucell
Adenovirus Pandemic inﬂuenza Paxvax
Adenovirus Pandemic inﬂuenza Vaxin
Attenuated inﬂuenza virus Inﬂuenza
HIV
TB
Polymun Scientiﬁc
Human or bovine PIV3 PIV3/RSV Medimmune
AstraZeneca
Recombinant modiﬁed vaccinia Ankara Measles Bavarian Nordic
Replication incompetent adenovector HSV GenVec
Replication incompetent adenovector HCV Okairos
Vaccinia virus HCV Transgene
Mid-stage development (Phase II)
Adenovirus Malaria
TB
Crucell
Adenovirus HIV Paxvax
Adeno-associated virus HIV Targeted Genetics
rMVA Cancer Oxford Biomedica
rMVA TB Emergent Biosolutions
rMVA Smallpox
Cancer
HIV
Bavarian Nordic
Replication incompetent adenovector HIV
Malaria
GenVec
Replication incompetent adenovector Malaria Okairos
rMVA Cancer
HPV
Transgene/Novartis
Transgene/Roche
Continued on next page
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TABLE 6.3. EXAMPLES OF VIRAL VECTOR CANDIDATE VACCINES IN VARIOUS STAGES OF CLINICAL
DEVELOPMENT e CONTINUED
Vector Pathogen target Manufacturer
Vaccinia and fowlpox Cancer Bavarian Nordic
Yellow fever virus Dengue
West Nile
Sanoﬁ Pasteur
Late-stage development (Phase III)
rMVA Cancer Oxford Biomedica
Canarypox virus HIV Sanoﬁ Pasteur
HIV, human immunodeﬁciency virus; HCV, hepatitis C virus; TB, tuberculosis; PIV3, human parainﬂuenza virus type 3; RSV, respiratory
syncytial virus; HSV, herpes simplex virus; rMVA, modiﬁed vaccinia virus Ankara; HPV, human papillomavirus. Every effort has been made to
verify the information in this table. The information included is not meant to be exhaustive but is intended to provide an overview of the
subject matter.
164 UNDERSTANDING MODERN VACCINESown right or a bacterial vector system to deliver exogenous
antigens; and b) to determine whether re-administration of the
vector, either with the same or different target antigens, will fail
because of the immune response to the bacterial vector vaccine at
the time of its initial administration.
Initial assessments of the feasibility of using attenuated bacterial
vectors for the delivery of foreign antigens have focused on
Salmonella species. Bacterial vaccine vectors for humans,
however, have been disappointing so far. It may be necessary to
develop unique bacterial vaccine vectors for delivering
exogenous antigens, in which case the vectors can be modiﬁed
to allow for re-use. For example, if immunity against the vector,
which is a major impediment to vaccine re-use, is determined by
antibodies against the surface structures of the bacterium (such
as lipopolysaccharide [LPS]), the dedicated vaccine vector could
be developed to lack expression of LPS or to express truncated/
different forms of LPS to the target, thereby avoiding priming of
the immune response and allowing for re-use of the vector and/or
vaccine. Some potential options for live, attenuated bacterial
vectors are shown in Table 6.4.
Figure 6.5 Bacterial vectors for vaccines. Antigen-encoding genes are isolated from the pathogen and inserted into endogenous bacterial
plasmid DNA. The bacterial vector can then be used as a factory for production of large quantities of pathogen antigen in vivo, following
administration of the bacterial vector to the vaccine recipient, with the pathogen antigen then displayed on the surface of the bacteria or secreted.
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DNA vaccines are the result of the discovery in the early 1990s
that the gene, rather than the encoded protein, if delivered in
an ‘expressible’ form, could induce an immune response (see
Chapter 1 e Vaccine evolution). The principle behind DNA
vaccines is that the antigenic molecule is produced within the
host from the DNA or RNA that is injected, in contrast to more
traditional vaccination where the antigen is supplied in the
vaccine formulation. The gene(s) for target antigen(s) is/are
usually encoded in a circular plasmid expression vector
under the control of promoter sequences that direct gene
expression in mammalian cells, which is achieved after injection
into mammals.
TABLE 6.4. BACTERIAL VECTOR VACCINES IN CLINICAL DEVELOPMENT
Vector Pathogen target Manufacturer/developer
Early-stage development (Phase I)
Salmonella typhi HIV
Helicobacter pylori
Streptococcus pneumoniae
Vaccine platform being developed under Gates
Foundation support at Arizona State University
Vibrio cholerae ETEC/cholera Celldex
Listeria monocytogenes HPV Advaxis
Mid-stage development (Phase II)
Salmonella typhi Typhoid Celldex
Salmonella typhi HBV
Typhoid
Emergent Biosolutions
Vibrio cholerae Cholera Celldex
HIV, human immunodeﬁciency virus; ETEC, enterotoxigenic Escherichia coli; HPV, human papillomavirus; HBV, hepatitis B virus. Every effort has
been made to verify the information in this table. The information included is not meant to be exhaustive but is intended to provide an overview of
the subject matter.
166 UNDERSTANDING MODERN VACCINESThe DNA vaccine process can circumvent some of the major issues
resulting from recombinant protein administration. The construction
and production of the plasmids carrying the gene of interest
together with the promoter sequences is relatively simple; antigens
expressed from plasmids retain their native conformation, the gene
can be readily modiﬁed to produce tailored antigens, and bacterial
plasmid DNA is intrinsically immunogenic (subsequently shown to
result from the pathogen-associated molecular patterns [PAMPs] it
carries). Additional desirable features include the ability to engineer
and deliver genetic adjuvants in tandem or parallel with the antigen,
the potential to deliver multiple antigen genes in one construct or
within other constructs that encode adjuvanting protein(s), and the
ability to induce both cellular and humoral immune responses.
Despite promising data in pre-clinical testing, DNA vaccine
candidates have shown only limited success in clinical settings so
far. One of the current drawbacks of DNA vaccines is the inefﬁciency
of conventional delivery methods for the plasmid DNA; however,
VACCINES OF THE FUTURE 167emerging proprietary particle-mediated delivery technology or
electroporation technology seeks to improve this situation. With the
electroporation method, brief electrical pulses are applied at the site
of immunisation which causes a transient disruption of cell
membranes. This results in an enhancement in uptake of the DNA
vaccine between 10e100-fold. Examples of DNA candidate
vaccines in clinical development are presented in Table 6.5.DC vaccines hold great promise for the
treatment of cancer, HIV and other
chronic infections. Utilising the patient’s
own DCs, this is truly an individualised
biomedical intervention.DENDRITIC CELL VACCINES
Dendritic cell (DC) vaccines typically usemonocytes harvested from
the blood (in most cases from the individual who will receive the
vaccine) to produce immature DCs in vitro. The monocytes are
antigen-loaded and treated to induce their maturation into APCs
and infused back into the patient. The ﬁrst Food and Drug
Administration (FDA)-approved DC vaccine, designed for the
treatment of prostate cancer, was licensed in 2010 (Sipuleucel-T);
examples of other targets for DC vaccine therapy are presented in
Table 6.6. DC vaccines offer an individualised approach to
therapeutic vaccine development, but represent a specialised
method of vaccination that is currently limited to aggressive
cancers, and the treatment of serious, intractable infections.
A comparison between the strengths and weaknesses of selected
new vaccine platforms is presented in Table 6.7.New approaches to vaccine
administration
Developing administration techniques that place the vaccine
directly at the site(s) where pathogens are most likely to initiate an
infection (eg mucosal or respiratory sites) is likely to improve
vaccine efﬁcacy and safety.
Traditional methods of vaccine administration can potentially
pose a number of limitations with respect to reactogenicity,
immunogenicity, convenience, efﬁcacy, safety andcost-effectiveness.
Most vaccines are administered by intramuscular (IM) injection, while
TABLE 6.5. DNA VACCINES IN CLINICAL DEVELOPMENT
Target Manufacturer
Early-stage development (Phase I)
HIV
Cancer
Ichor
HPV
Cancer
Inovio
Inﬂuenza
HBV
PowderMed/Pﬁzer Vaccines
Melanoma Memorial Sloan-Kettering Cancer Center
Cancer
Pandemic inﬂuenza
SARS
Ebola
West Nile
Anthrax
Vical
Mid-stage development (Phase II)
HIV FIT Biotech
HBV
HIV
Genexine
Acute myelocytic leukaemia Immunomic Therapeutics
Cancer
HCV
Inovio
CMV
HIV
Vical
Late-stage development (Phase III)
Melanoma Vical
HIV, human immunodeﬁciency virus; HPV, human papillomavirus; HBV, hepatitis B
virus; SARS, severe acute respiratory syndrome; HCV, hepatitis C virus;
CMV, cytomegalovirus. Every effort has been made to verify the information in this
table. The information included is not meant to be exhaustive but is intended to
provide an overview of the subject matter.
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TABLE 6.6. DC VACCINES AND CANDIDATE VACCINES LICENSED AND IN CLINICAL DEVELOPMENT
Target Stage of development Manufacturer
Melanoma Phase I (therapeutic) Immutep
HIV Phase I (therapeutic) Baylor Research Institute
Melanoma Phase II (therapeutic) Immutep
Prostate cancer FDA licensed 2010 Dendreon
HIV, human immunodeﬁciency virus; FDA, Food and Drug Administration. Every effort has been made to verify the information in this table.
The information included is not meant to be exhaustive but is intended to provide an overview of the subject matter.
TABLE 6.7. ADVANTAGES AND DISADVANTAGES OF VIRAL, BACTERIAL, DNA AND DC-BASED VACCINES
Advantages Disadvantages
Viral vectors
Use pathways that induce robust and durable cellular and
humoral immunity
May be applied to the mucosal surface (facilitating
oral delivery)
Easily engineered
Potential for lack of attenuation of the vector
Potential for over-attenuation with associated poor immunogenicity
Risk of recombination resulting in restored virulence
Efﬁcacy decreased by pre-existing vector immunity
Vector-speciﬁc responses may limit subsequent doses
Potential for some vectors to establish persistent/latent infection
Bacterial vectors
Directed delivery of target antigen to speciﬁc cells including
macrophages
Large antigen-carrying capacity
Safety maximised by removing several genes
Potential for mucosal immunity
Oral delivery possible
Possible genomic instability at the site of insertion giving low antigen
expression levels
Expression of bacterial antigens may further reduce vaccine-speciﬁc
immunogenicity
Efﬁcacy decreased by existing vector immunity
Difﬁcult to optimise engineering without conducting a number of clinical trials
DNA vaccines
Deﬁned composition
Non-replicating platform capable of inducing T-cell immunity
Potential application in development of therapeutic vaccines
Construct may code for multiple epitopes and also inducers
of innate immune responses
Poor immunogenicity in humans
Concerns/issues regarding potential for construct to integrate with
host genome
Continued on next page
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TABLE 6.7. ADVANTAGES AND DISADVANTAGES OF VIRAL, BACTERIAL, DNA AND DC-BASED VACCINES
e CONTINUED
Advantages Disadvantages
DC vaccines
Individualised approach to therapeutic vaccine development
Can induce potent T-cell responses
Clinical responses can be achieved
Expensive (these vaccines typically use autologous DCs) with
sophisticated logistics
Mature DCs rapidly lose viability and function after injection
Difﬁcult to achieve clinically sufﬁcient levels of circulating antigen-speciﬁc Tcells
DC, dendritic cell.
Transdermal microneedle patch vaccine
administration utilises an array of
microneedles (Figure 6.6) to deliver
the vaccine to the epidermis, which is
rich in innate and adaptive immune
response elements.
170 UNDERSTANDING MODERN VACCINESselected vaccines are delivered intranasally (eg via droplet for live
attenuated inﬂuenza vaccine and via aerosol for measles vaccine); by
the oral route (eg polio and rotavirus vaccines); or subcutaneously
(particularly live viral vaccines such as the measles-mumps-rubella
[MMR] vaccine and varicella zoster-containing vaccines).
Ongoing research on alternative experimental administration
strategies includes ballistic delivery to skin (the gene gun), the
transdermal patch and other intradermal methods, plus sublingual,
aerosol, rectal and vaginal mucosal vaccines. The main
advantages of alternative delivery strategies are the potential to
induce immune responses at the common portals of pathogen
entry (eg oral polio vaccine replicating in the gut), potential
convenience (eg ease of use of the transdermal patch), potential
combination of vaccines to reduce or simplify the vaccination
schedule, and reduction or elimination of administration via
standard hypodermic needle injection. Despite the intuitive value of
these approaches, few vaccines today are administered via non-IM
routes. This is for several reasons including feasibility, lack of
proven efﬁcacy and limited safety data. Some problems have been
observed with new routes of delivery, for example, after the 2000
launch of an inactivated intranasal inﬂuenza vaccine (a virosome
formulation adjuvanted by heat labile enterotoxoid of Escherichia
coli), post-licensure data indicated a signiﬁcantly increased risk of
Bell’s palsy in vaccinees and forced its withdrawal from the market.
This experience led to a higher level of caution in the development of
intranasal vaccines.
Figure 6.6 Microneedles. An alternative to IM injection for vaccine administration is the use of a transdermal patch containing an array of
microneedles, typically <1 mm long; much shorter and less intrusive than the needles typically used for IM injections (20e30 mm in
length) (A). Microneedles pierce the epidermis of the skin, a site rich in innate and adaptive immune response elements, and deliver the
vaccine antigen painlessly. Adhesive, needle-free transdermal patches are also in development (B).
IM, intramuscular.
A
B
Adhesive transdermal
patch
IM needle
Microneedle
(22 mm)
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Aerosol delivery: ‘Mass immunization of
almost all susceptible children in a short
period of time, has the potential of rapidly
eliminating measles as a public health
problem. Immunization by inhalation of
aerosolised measles vaccine provides
a procedure that couldmake such amass
programmepossible, especially inparts of
the world where measles continues to be
a serious problem.’ (Sabin et al., 1983).
Administering the measles vaccine as an
aerosol, either as nebulised vaccine or as
a dry powder, provides a promising
alternative to subcutaneous
administration, particularly in countries
with concerns over inadequately safe
injection practices. Numerous clinical
trials with aerosolised measles vaccine
have been performed in populations of
various ages and appear to be equally or
more immunogenic than subcutaneous
vaccination in adults and children over
9 months old (data from younger children
are inconclusive, possibly because of
administration difﬁculties). Measles
vaccine is not currently licensed for
respiratory administration, though this
route is being comprehensively studied
by theWorld Health Organization’s (WHO)
Measles Aerosol Project and a Phase II/III
study is underway in India to conﬁrm that
the efﬁcacy of inhaledmeasles vaccine is
equivalent to that of existing routes of
administration. In parallel, various
delivery devices are in development.
172 UNDERSTANDING MODERN VACCINESNew vaccines for complex and
challenging targets
In the future, new vaccines will target not only important established
infectious diseases (eg malaria, TB, HIV, Lassa fever, severe acute
respiratory syndrome [SARS]), but also emerging or yet to be
discovered infectious diseases. New vaccines may also target
diseases that result in illnesses manifesting as autoimmune
disease (eg diabetes mellitus, multiple sclerosis) or chronic
inﬂammation. New vaccines are likely to address the problem of
immunosenescence in the elderly; and therapeutic vaccines may
offer new treatments for the control of persistent infectious
diseases, cancer and illnesses such as Alzheimer’s disease.VACCINES ADDRESSING PERSISTENT INFECTION
AND MALIGNANCY
Persistent infections include both chronic infections, characterised
by ongoing replication of the pathogen (eg chronic hepatitis B virus
[HBV] and hepatitis C virus [HCV] infections, malaria, Helicobacter
pylori infections); and latent infections, where the pathogen, after
the ﬁrst infection, remains dormant in the host until triggered to
reactivate (eg recurrent herpes simplex virus [HSV] infection, herpes
zoster, reactivation TB). Since the natural immune responses in
persistently infected hosts fail to clear the infection, mimicking
the immune response to natural infection with immunisation may
not be sufﬁcient.
Today, the only example of a licensed vaccine against a latent
infection is the zoster vaccine; the vaccine formulation is the high
potency (about 15-fold) version of the live, attenuated varicella
zoster virus (VZV) vaccine. This vaccine has been used to boost the
anti-VZV cell-mediated immune response in older subjects and has
been shown to reduce the overall incidence of zoster by 50% in
subjects aged 60 years or older (Oxman et al., 2005).
Future vaccines may control persistent infections either by
preventing the initial infection or disease (ie prophylactic vaccines)
The issue of whether a vaccine protects
against infection or disease is critical
with regard to pathogens capable of
establishing persistent infection. While
a vaccine that protects against disease
may afford some beneﬁt, if the vaccine
fails to prevent initial infection, the
pathogen may establish a persistent
VACCINES OF THE FUTURE 173or by augmenting or redirecting immune responses in the
persistently infected host in order to eliminate or control the chronic
infection (ie therapeutic vaccines).
An increased understanding of human immunology and of
hostepathogen interactions should enable the identiﬁcation of the
type(s) of immunity required to effectively prevent or control
persistent infections (see Chapter 2 e Vaccine immunology). Some
examples of persistent infections are shown in Table 6.8.infection with long-term disease
consequences, such as recurrent
infection, organ damage or malignancy.
Therapeutic vaccines are designed to
stimulate an immune response that can
control or cure persistent infections,
malignancies, autoimmune diseases,
degenerative diseases or addiction.
This approach may enhance existing
responses, engender new responses,
or alter the existing balance of
immune responses. It is important to
make the distinction between this
immunotherapeutic application of
vaccine technology and prophylactic
vaccines that prevent infection/disease
from occurring, although similar immune
mechanisms are involved e see
Prophylactic and therapeutic vaccines
for cancer.Tuberculosis
Mycobacterium tuberculosis can persist in a latent state within the
human host for years without causing disease (latent TB). Protection
against miliary (disseminated) TB in children is provided by the
bacille CalmetteeGuérin (BCG) vaccine, developed through culture
attenuation ofMycobacterium bovis early in the 20th century, which is
routinely given in many countries. The vaccine, however, provides
only modest and often temporary protection against pulmonary TB,
and provides lower efﬁcacy in resource-limited regions closer to the
equator. In addition, vaccination with live, attenuatedMycobacterium
bovis is a particular concern in HIV-positive individuals, especially
those with advanced immune suppression; this population would
particularly beneﬁt from TB vaccination as TB is a leading cause of
death worldwide for people with HIV/acquired immunodeﬁciency
syndrome (AIDS). However, a recent Phase III trial demonstrated that
protection against TB can be provided to individuals with HIV by
using an inactivated whole-cell mycobacterial vaccine (von Reyn
et al., 2010). The current state of TB vaccine development has been
summarised in reviews by Walker et al. (2010) and Lambert et al.
(2009) and examples of vaccines in development are shown
in Table 6.9.Cytomegalovirus
Cytomegalovirus, a herpes virus, establishes latent infection in
cells in the bone marrow and peripheral blood. Primary infection
during pregnancy is associated with congenital infection that
TABLE 6.8. PATHOGENS CAPABLE OF ESTABLISHING PERSISTENT INFECTIONS
Pathogen Type of persistent
infection
Disease
Hepatitis viruses B, C, D and E
(in immunocompromised patients)
Chronic Chronic hepatitis, cirrhosis, malignancy
HIV Chronic HIV/AIDS
Papovaviruses Chronic Progressive multifocal leukoencephalopathy
Prions Chronic Spongiform encephalopathies
Helicobacter pylori Chronic Chronic gastritis, gastric and duodenal ulcers, and gastric
and duodenal cancer
HPV Chronic Cervical cancer, other genital and oral cancers
HSV Latent Recurrent HSV infections, HSV encephalitis
VZV Latent Zoster
EBV Latent Reactivation diseases including glandular fever and
nasopharyngeal carcinoma
Mycobacterium tuberculosis Latent Reactivation TB
CMV Latent Severe multisystem reactivation disease in
immunocompromised patients
HIV, human immunodeﬁciency virus; AIDS, acquired immunodeﬁciency syndrome; HPV, human papillomavirus; HSV, herpes simplex virus;
VZV, varicella zoster virus; EBV, EpsteineBarr virus; TB, tuberculosis; CMV, cytomegalovirus. Every effort has been made to verify the
information in the above table. The information included is not meant to be exhaustive but is intended to provide an overview of the
subject matter.
174 UNDERSTANDING MODERN VACCINESfrequently causes a well-characterised spectrum of abnormalities
and disabilities, which may be severe or fatal. Reactivation in
pregnancy is common, but is unlikely to cause severe congenital
infection, although some manifestations, especially hearing loss,
remain common. Reactivation of CMV is of special concern in
immunocompromised individuals, where severe and fatal
pulmonary, hepatic and central nervous system infections are
common. Gastrointestinal disease and retinitis are common in
association with HIV. A successful CMV vaccine has proved elusive
for more than 30 years. Based upon the observation that
antibodies to the CMV envelope glycoprotein B (gB) could
TABLE 6.9. EXAMPLES OF MYCOBACTERIUM TUBERCULOSIS VACCINES IN DEVELOPMENT
Approach Vaccine name Comment Manufacturer
Early-stage development (Phase I)
TLR9 agonist, fusion protein H4 SSI HyVac4 (AERAS-404) Adjuvanted with IC31 Statens Serum Institut, Sanoﬁ Pasteur,
Intercell and Aeras
Mid-stage development (Phase II)
Fusion protein GSK M72 Adjuvanted with AS01 GSK Biologicals
Adenovirus vector 35 Crucell Ad35
(AERAS-402)
Viral vector Crucell
Modiﬁed vaccinia Ankara virus MVA85A (AERAS-485) Viral vector The Oxford-Emergent TB Consortium Ltd
TLR, Toll-like receptor; SSI, Statens Serum Institut; AERAS, The Aeras Global TB Vaccine Foundation; GSK, GlaxoSmithKline; AS, Adjuvant
Systems; MVA, modiﬁed vaccinia Ankara. Every effort has been made to verify the information in this table. The information included is not meant
to be exhaustive but is intended to provide an overview of the subject matter.
VACCINES OF THE FUTURE 175neutralise the virus, and with the advent of genetically engineered
viral proteins, new research began in the late 1980s on a CMV
gB subunit vaccine. This included the use of a novel adjuvant,
MF59 (Pass et al., 1999). A recent Phase II clinical trial in
CMV-seronegative women 1 year post-partum has shown the
potential of gB/MF59 in decreasing incident cases of maternal and
congenital CMV infection (Pass et al., 2009). This is the ﬁrst
evidence that a CMV vaccine can protect against infection.
An alternative approach to the development of a CMV vaccine has
been to utilise DNA vaccination to induce host responses to
CMV gB and phosphoprotein 65 (pp65 is another viral target).
Recent studies have shown that injection of combinations
of plasmids, formulated with an adjuvant, can induce
vaccine-speciﬁc immune responses, and can prime for effective
memory responses.Herpes simplex virus
The hallmark of herpes simplex virus types 1 and 2 (HSV-1 and
HSV-2) is their ability to establish and maintain latent infection in
TABLE 6.10. POSSIBLE EFFECTS AND CONSEQU
Effect Positive conseque
Prevent mucosal infection No clinical disease
No latency
No recurrences
Prevent development of clinical
disease but not mucosal infection
No symptomatic dis
Prevent latent infection No latency and no r
Reduce latent infection Possibly fewer recu
outbreaks, and less
HSV, herpes simplex virus.
176 UNDERSTANDING MODERN VACCINESsensory ganglion neurons. Periodic reactivation of the latent
infection results in recurrent infections. Both HSV-1 and HSV-2
can cause myriad diseases but the greatest public health
problem is genital herpes. Genital HSV-2 infection increases
the risk of HIV acquisition and transmission, and control of
genital herpes has been predicted to signiﬁcantly impact the
HIV epidemic. Given the complex natural history of HSV
infections, vaccines could have a variety of possible risks and
beneﬁts (Table 6.10).
An effective HSV vaccine has been sought for more than 80
years. Recently, an HSV-2 glycoprotein D (gD2) candidate
vaccine containing the AS04 adjuvant (see Chapter 4 e Vaccine
adjuvants), was tested in three large, double-blind, Phase III
controlled trials. The ﬁrst two studies recruited volunteers with
a partner with genital herpes disease and found the candidate
vaccine was 73% effective against genital herpes disease in
women seronegative for both HSV-1 and HSV-2 (Stanberry et al.,
2002). Trends towards protection against infection were also
observed, but were not statistically signiﬁcant. The candidate
vaccine was not effective in HSV-1 seropositive women; or inENCES OF GENITAL HSV VACCINES
nces Negative consequences
None
ease Latency established
Recurrent infections can develop with possible
transmission to susceptible partners
ecurrences Without preventing mucosal infection there could be
an initial episode of symptomatic genital herpes
rrences or less severe
risk of transmission
Still a risk of initial and recurrent infections and hence
transmission
VACCINES OF THE FUTURE 177men, regardless of their HSV seropositivity status. These were
the ﬁrst studies to report a signiﬁcant difference in vaccine
efﬁcacy between men and women. This ﬁnding could have
important implications for other vaccines targeting sexually
transmitted diseases. The basis for this difference could relate to
differences in how men and women respond to novel adjuvants
or may reﬂect differences in the acquisition and natural history of
genital herpes in men and women. A third Phase III efﬁcacy trial
of the gD2 candidate vaccine in HSV-1 and HSV-2 negative
women who thought themselves possibly at risk of acquiring
genital herpes (a different risk population than in the original two
trials) has been completed and is being analysed. An initial
assessment of the results of the third trial showed that
the vaccine had an acceptable safety proﬁle but the primary
trial endpoint, prevention of genital herpes disease, was not met
(NIAID, 2010). Although the development of the vaccine has
been stopped, further analyses and comparison of the trials may
guide researchers as they continue seeking vaccines to control
HSV infections.
VACCINES FOR PATHOGENS WITH A COMPLEX LIFE
CYCLE
As discussed in Chapter 2 e Vaccine immunology, some pathogens
have complex life cycles. One speciﬁc example is parasites,
sometimes using more than a single host, where each development
phase ismarked by differential expression ofmajor proteins,meaning
that possible antigen targets are host- and development-phase
speciﬁc. Taenid worms aside, vaccines against parasites have been
extremely difﬁcult to develop and only a limited number have
performed well in later-stage clinical trials.
Plasmodium falciparum
The protozoan parasite Plasmodium falciparum, the most common
cause of malaria, has a complex life cycle, as shown in Figure 6.7.
The Plasmodium parasite has a genome encoding more than
5000 proteins, and presents different allelic and immunogenic
Figure 6.7 The life cycle of Plasmodium falciparum with stages identiﬁed for vaccine development. The parasite responsible for malaria is
delivered as sporozoites to the host during a blood feed by a carrier Anopheles spp mosquito. Sporozoites travel to the liver, and develop into
merozoites. Infected hepatocytes rupture, releasing merozoites into the bloodstream. The infection becomes symptomatic as increasing
numbers of red blood cells are invaded by merozoites. The merozoites can also develop into male and female gametocytes, lysing the blood
cells upon maturation. A blood feed by another mosquito allows uptake of the gametocytes. Sexual reproduction within the mosquito
generates oocysts that eventually rupture and release sporozoites that subsequently migrate to the mosquito’s salivary gland to restart the life
cycle when the mosquito feeds. Candidate vaccines have been designed to target the pre-erythrocytic, blood and transmission stages of the
life cycle.
In the mosquito
In the liver
In the 
bloodstream
178 UNDERSTANDING MODERN VACCINESstructures at each stage of the life cycle. Many of the key antigens
are subject to antigenic variation. The complexity of the Plasmodia
has made the development of an effective malaria vaccine
extremely challenging. Over the past 30 years there have been more
VACCINES OF THE FUTURE 179than 90 candidate vaccines that have not reached advanced
stages of development.
A number of new malaria candidate vaccines that utilise adjuvants
or viral vectors are presently in clinical trials (see Appendices,
Supplementary Table 7). One of the furthest advanced of these new
candidate vaccines is RTS,S/AS01. The vaccine targets the
pre-erythrocytic stage of the parasite (Figure 6.7). To be protective,
a vaccine targeted at this phase needs to induce humoral immunity,
to prevent parasites from invading the liver, and cell-mediated
immunity to destroy hepatocytes that become infected in the face
of the humoral immune response. The RTS,S antigen, produced in
Saccharomyces cerevisiae, contains sequences of the P. falciparum
circumsporozoite protein, linked to the hepatitis B surface antigen
(HBsAg). This chimeric protein spontaneously assembles into
mixed polymeric particulate structures. In Phase II studies, the
RTS,S/AS01 candidate vaccine induced a strong neutralising
antibody response and cell-mediated immunity, and afforded
protection against malaria (Bejon et al., 2008; Abdulla et al., 2008).
RTS,S/AS01 has been selected to proceed to Phase III clinical
testing due to its higher efﬁcacy compared with alternative
formulations. If successful, the RTS,S/AS01 candidate vaccine
could be the ﬁrst licensed human vaccine against a parasite. Other
malaria candidate vaccines in development are shown in
Appendices, Supplementary Table 7.
VACCINES AGAINST PATHOGENS THAT EXHIBIT
ANTIGENIC VARIABILITY
Pathogens may mutate or recombine to change their antigenic
proﬁle. Antigenic drift refers to a gradual process whereby point
mutations in genes encoding antigenic proteins change the antigen
sufﬁciently so that over time previously effective antibodies and
vaccines no longer effectively control the pathogen and hence new
vaccines need to be created. Antigenic shift is a more dramatic
event where there is a recombination of genes between different
pathogen strains that gives rise to a new strain with a unique
antigenic proﬁle.
180 UNDERSTANDING MODERN VACCINESIn theory, pathogens are susceptible to selective pressure and an
immunological environment that provides strong selective
pressures should provide the ‘bottleneck’ that drives selection. This
occurs with inﬂuenza viruses, where the high mutation frequency
allows for the selection of mutants that are not neutralised. The risk
of vaccine-mediated immune selection of pathogens, though
certainly present, is difﬁcult to demonstrate. Moreover, peptide
vaccines only use the antigenic epitope so the risk of pathogen
evolution is theoretically increased. However, this phenomenon has
not been regularly observed in experimental studies and may reﬂect
the complex nature of most vaccine antigens and the presence of
immune responses against multiple antigens and multiple epitopes
within antigens.
Serotype replacement, where the distribution of speciﬁc microbial
serotypes within communities changes after the introduction of
vaccines, has occurred for some bacterial pathogens and may be
a consequence of the use of capsular vaccines that address only
a limited number of serotypes.
Similarly, since their introduction in the 1940s, the use of
antibiotics has exerted a selective pressure on bacterial strains
leading to selection for common resistance alleles (eg the
extended-spectrum beta-lactamase [ESBL] resistance of enteric
bacteria and beta-lactamase resistance in gonococci). To date,
there has been no requirement to remodel a vaccine because of
vaccine-mediated immune escape; however, new vaccines
against the pneumococcus have been licensed, including
additional capsular types, to expand the geographical coverage of
most frequent types and, in part, to counter the observed
phenomenon of serotype replacement. Annual seasonal
inﬂuenza infections are subject to natural antigenic drift which
requires the reformulation of the vaccine when drifts occur, but
there is no evidence that the deployment of the vaccine accelerates
this drift.
Antigenic shift, while not the result of selective pressure, gives rise to
viral strains containing a mixture of the surface antigens from the
parent strains. Pathogens that can undergo antigenic shift,
Figure 6.8 Antigenic shift resulting in a new inﬂuenza virus.When two (ormore) inﬂuenza viruses infect the samehost cell, genetic segments fromboth
strains can becomepackaged into the sameprogeny virion. This results in a new virus strain that displays a distinct and varying array of surface antigens,
relative to the parent strains. The shifted strains are all possible candidates for a pandemic infection due to their new features to which most of the
population is naïve.
HA, haemagglutinin; NA, neuraminidase.
Replication
of two viruses
in the same
host cell
Host
cell
Possible new virus from
genetic reassortment
VACCINES OF THE FUTURE 181including inﬂuenza viruses (Figure 6.8), present major challenges
for vaccine developers.
Nevertheless, as described in Chapter 3 e Vaccine antigens and
Chapter 4 e Vaccine adjuvants, there has been progress in the
TABLE 6.11. RESEARCH TO DEVELOP NEW INFLUENZA VACCINES CONTINUES
Research area Research goal
Alternative methods for antigen delivery Virus-like particle vaccines
Recombinant vector vaccines
Use of adjuvants Enhance immunogenicity and reduce dose
Overcome immunosenescence
Antigen presentation, concentration and use of
conserved sequences
Re-explore the development of DNA vaccines
Utilise conserved viral antigens in the development of a universal vaccine
A Phase III clinical trial combining Global
Solutions for Infectious Diseases’
AIDSVAX with Sanoﬁ Pasteur’s
recombinant canarypox vector vaccine
(ALVAC) expressing CRF-AE gp120 and
subtype B Gag, Pol and Nef antigens
(surface glycoproteins, replication
enzymes and non-structural accessory
proteins, respectively) was modestly
successful with an efﬁcacy of 31.2%
(95% conﬁdence interval, 1.152.1;
p[0.04) against HIV infection in 16,000
Thai volunteers. The vaccine purposely
targeted HIV-1 strains speciﬁc to
Thailand (Rerks-Ngarm et al., 2009). This
trial was the ﬁrst to show a degree of
efﬁcacy for an HIV candidate vaccine.
182 UNDERSTANDING MODERN VACCINESdevelopment of inﬂuenza vaccines that target strains against which
the vaccinee has limited or no pre-existing immunity, arising as the
result of antigenic drift and shift (Table 6.11).
Another approach to the problem of inﬂuenza genome shifts has
been to target weakly immunogenic conserved antigens such as
the inﬂuenza M2e protein. One approach to addressing the weak
immunogenicity of the antigen has been to link it to a potent Toll-like
receptor adjuvant such as ﬂagellin, an approach developed by
VaxInnate Inc.
Human immunodeﬁciency virus
During primary infection of a single individual with HIV, mutations in
surface proteins of the virus lead to selection of a ‘cloud’ of
antigenic variants that can evade the cell-mediated immune
responses complicating the development of broadly effective
vaccines. This propensity for mutation has given rise to many
strains of HIV (Figure 6.9). Two types of HIV, HIV-1 and HIV-2, have
been identiﬁed, with HIV-1 being the most common. On a global
scale, HIV-1 strains are differentiated according to their respective
group and subtypes (or ‘clades’) within groups. The amino acid
sequence of the viral envelope glycoprotein gp120 shows 25e35%
divergence between clades and up to 20% divergence within any
given clade, which constitutes a formidable hurdle to vaccine
development. This is made worse by recombination between
clades of HIV-1, which has produced circulating recombinant
forms (CRFs) which differ in antigenicity depending on the
geographical region.
Figure 6.9 Division of HIV-1 subtypes. Mutations of HIV have given rise to many
clades and region-speciﬁc combinations of clades, known as CRFs, of which some
examples are shown. The genetic variation between HIV clades and CRFs has
challenging implications for the development of HIV vaccines; future HIV vaccines may
need to be clade- or region-speciﬁc, or cross-protective for all clades, groups and types.
Circulating
HIV, human immunodeﬁciency virus; CRFs, circulating recombinant forms.
Development of HIV vaccines:
the toughest task?
Development of a vaccine for HIV/AIDS
is exceptionally difﬁcult due to HIV
targeting of key immune cells during
infection; the marked variability in HIV
strain sequence and antigenicity
between and within individuals; the
lack of understanding of successful
immune control; and the failure to
reproduce in humans the results of
successful vaccine trials in monkey
(simian immunodeﬁciency virus [SIV])
models. Recent human trials aimed at
inducing CD8þ lymphocyte cytotoxicity
(the key immune effector in SIV trials)
have failed, probably because the
induced repertoire lacks sufﬁcient
potency and breadth of speciﬁcity.
Vaccine development has been spurred
however, by the ability of human ‘elite
controllers’ and old world monkeys to
control viral load and/or disease; by the
recent demonstration that broad
neutralising antibody to HIV can be
induced in humans; and by the 2009
‘Thai vaccine trial’ which demonstrated,
for the ﬁrst time, limited efﬁcacy of an
HIV vaccine.
VACCINES OF THE FUTURE 183Since the initiation of HIV vaccine programmes, more than 30
candidate vaccines have been tested in over 80 Phase I/II clinical trials
involving more than 10,000 healthy human volunteers. Regrettably, all
attempts to date have failed to yield a licensed HIV vaccine.
Questions remain concerning the immune mechanisms behind
vaccines that achieve partial protection. Regardless of the
unknowns, the ability to prevent infection in at least some individuals
still offers real hope that a globally effective HIV vaccine might be
possible. Current research is comparing the immune responses of
subjects who are naturally protected against HIV with those who
were infected, seeking to ﬁnd the elusive immunological
mechanisms of protection to help guide the design of future T-cell
vaccines against the virus.
Group A Streptococcus
Infections of group A streptococcal serotypes (ie Streptococcus
pyogenes) account for approximately 85% of cases of
Targets of HIV/AIDS vaccine
candidates
Current vaccine candidates are aimed at
inducing multiple types of immune
effectors with a single vaccine. These
effectors include CD4þ and CD8þ T-cell
lymphocytes of increased potency and
breadth, and broad neutralising and
perhaps non-neutralising antibody, to
handle the many circulating HIV strains.
The 2009 ‘Thai vaccine trial’ suggested
a need to examine the role of non-
neutralising antibody and the possibility
of preventing HIV acquisition, not just
progressive immunodeﬁciency. A better
understanding of the multiple subsets of
CD4þ lymphocytes in HIV infection and
the role of DCs as initial targets for
infection are at the forefront of these new
efforts. New hybrid viral vectors,
synthetic antigens (developed with the
aid of three-dimensional modelling),
novel adjuvants that manipulate the
immune system to induce desirable
responses and more useful animal
models are also being developed
and tested.
Development of vaccines that induce
broad neutralising antibodies to highly
variable viruses, such as HIV and
inﬂuenza, has proved to be extremely
difﬁcult. However, screening HIV-infected
individuals for such antibodies has
allowed the identiﬁcation of previously
undiscovered viral epitopeswhich can be
incorporated into structure-based
vaccine design.
184 UNDERSTANDING MODERN VACCINESuncomplicated bacterial pharyngitis and streptococcal invasive
infections in North America. The M protein of group A streptococci
is a major virulence determinant of these organisms and also
functions as a major target for protective antibodies. One of
several strategies for vaccine prevention of these infections is
based on type-speciﬁc M protein epitopes. However, group
A streptococcal vaccine development faces many obstacles:
i) the widespread diversity of circulating M protein types; ii)
immunological cross-reactivity between epitopes in the M protein
and several human tissues introducing an autoimmune risk; and
iii) animal models are of limited value because humans are the
only hosts for group A streptococci. In an attempt to partially
overcome some of these obstacles, a design strategy akin to
that of the pneumococcal polysaccharide vaccines has been
employed to generate a group A streptococci multivalent
M protein-based vaccine containing type-speciﬁc determinants
from 26 different M serotypes. This multivalent vaccine is currently
in clinical development.The ‘prime-boost’ approach
The term ‘prime boost’ (or heterologous boosting) describes an
approach to vaccination where one type of vaccine, such as a
live-vector vaccine, is administered followed by a second type of
vaccine, such as a recombinant subunit vaccine. This is in
contrast with the traditional method of homologous boosting in
which two or more doses of the same vaccine are given
successively. The intent of prime-boost vaccination is to induce
different types of immune responses and enhance the overall
immune response, a result that may not occur if only one type of
vaccine were to be given for all doses. This approach has been
employed in trials with, for example, TB, CMV, malaria and HIV
candidate vaccines. For example, in studies on new TB vaccines,
subjects already primed with the live, attenuated BCG vaccine
have been boosted with a subunit adjuvanted vaccine
(see Tuberculosis).
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BY VACCINES
Respiratory syncytial virus
Respiratory syncytial virus is a common cause of bronchiolitis and
pneumonia in infants, and exacerbations of chronic obstructive
pulmonary disease in the elderly. The development of an effective
vaccine has been challenging; natural immunity to RSV infection is
incomplete and re-infections occur in all age groups. Moreover, the
primary target population for vaccination is newborns and young
infants, and they are a challenging population as they have
relatively immature immune systems and the presence of maternal
antibodies may interfere with vaccination of the young infant (see
Chapter 2 e Vaccine immunology). The initial efforts to develop
a formalin-inactivated cell culture-derived RSV vaccine resulted in
an unanticipated enhancement of natural RSV disease in some of
the RSV-naïve infants who received the vaccine in a clinical trial
and subsequently were exposed to RSV. The exacerbated
disease is thought to be due to an exaggerated T helper type 2
cell immune response (see Chapter 2 e Vaccine immunology).
Safety concerns regarding the potential of vaccines to trigger or
prime for immunopathological responses has resulted in
a cautious approach to the development of RSV vaccines. The
vaccine candidates most advanced in clinical development
use two different approaches e one uses a live, attenuated
virus with a gene deletion deliberately targeted to minimise
immunopathological responses. The other approach uses a live
viral vector to deliver only a key RSV surface antigen, thereby
avoiding the risk of an immunopathological response arising from
exposure to the RSV virus itself.
VACCINES FOR NEGLECTED TROPICAL
AND NON-TROPICAL DISEASES
Infectious illnesses exert a major burden of disease in developing
countries. The greatest burden is caused by diseases for which we
currently have no vaccines, eg taeniid cestode parasites are
associated with high human morbidity and losses in livestock.
Human Hookworm Vaccine
Initiative featured in Case
Studies for Global Health
The Human Hookworm Vaccine Initiative
(HHVI), an international product
development partnership based at the
Sabin Vaccine Institute, was established
in 2000 to develop the world’s ﬁrst ever
safe, affordable, multivalent
recombinant vaccine against human
hookworm infection. Such a vaccine
could impact an estimated 3.2 billion at
risk individuals. Sabin Vaccine’s HHVI is
one of 32 projects chosen for inclusion in
Case Studies for Global Health released on
20 November 2009 by the Alliance for
Case Studies for Global Health. Other
diseases includeHIV, TBandmalaria, and
lesser-known diseases such as dengue
fever and Japanese encephalitis. The
Alliance is a collaboration of The Bill &
Melinda Gates Foundation, the World
Health Organization’s Special
Programme for Research and Training in
Tropical Diseases (TDR), Global Health
Progress (GHP), the International AIDS
Vaccine Initiative (IAVI) and the
Association of University Technology
Managers (AUTM).
186 UNDERSTANDING MODERN VACCINESGlobal efforts to reduce these infections in humans are ongoing
through the use of antihelminthics and the implementation of
lifestyle changes, but this is having little effect. However, substantial
progress has been made towards developing veterinary vaccines
which encourages investigation of the potential use of similar
vaccines in humans to prevent, for example, hydatid disease
(arising from infection with Echinococcus granulosus) and
cysticercosis (from infection with Taenia solium).
Relative to their burden on society, such diseases have a low priority
for funding. Unless comprehensive measures are taken to address
the gaps in funding, research and global immunisation coverage,
developing countries will continue to be overwhelmed by some of
the most devastating diseases. In order to improve the situation,
collaborative schemes are underway that bring together academic
institutions, industry and public/charitable ﬁnancing organisations.
Recent initiatives include the Novartis Vaccines Institute for Global
Health, the MSDeWellcome Trust Hilleman Laboratories and the
Alliance for Case Studies for Global Health.VACCINES FOR NOVEL AND EMERGING PATHOGENS
It is estimated that 99% ofmicrobes are yet to be discovered. Using
nucleic acid sequencing strategies, Ian Lipkin has discovered close
to 200 new viruses including the LuJo virus, a new arenavirus that
has caused several fatal cases of haemorrhagic fever in Zambia
and South Africa. Behavioural and environmental changes may
facilitate the emergence and spread of new pathogens, while novel
methods of discovery may allow for the more rapid development of
vaccines against emergent diseases, before the new pathogens
become widespread public health problems, as was the case in the
development of a Sanoﬁ Pasteur vaccine against the SARS
coronavirus infection.
The microbiome, a term coined by Joshua Lederberg, is deﬁned as
the totality of microbes within a deﬁned environment. The human
microbiota has co-evolved with their hosts and appears to play
important roles in human health and disease. The Human
VACCINES OF THE FUTURE 187Microbiome Project is a National Institutes of Health initiative that
seeks to determine the relationship between human health and
changes in the human microbiome. By using revolutionary
sequencing technologies to characterise the microbiology of ﬁve
body sites e oral cavity, skin, vagina, gut and nasal tract/lung e an
association may be made between the microbiomes associated
with either the healthy body state or disease. Characterising
microbes associated with disease-related pathogens may allow for
the development of new vaccines that preserve or protect the
healthy microbiome and hence could protect human health. Some
of the areas of current research are outlined in the box, right.Diseases being explored in connection
with the human microbiome include
psoriasis and atopic dermatitis,
inﬂammatory bowel disease, urethritis
and sexually transmitted diseases,
obesity, oesophageal adenocarcinoma,
necrotising enterocolitis and paediatric
abdominal pain.Vaccines for conditions not generally
associated with infectious diseases
Some conditions traditionally thought of as non-infectious may in
fact have infectious origins (Table 6.12); therefore, vaccination could
be a strategy to prevent these diseases. Other diseases may result
from an interaction between the host’s genetic background and
a particular microbe (a so-called gene-environment interaction).
Some diseases have an established link with an identiﬁed infectious
agent. For example, primary CMV infection is a known cause of
congenital mental retardation; similarly the link between bacterial
vaginosis and foetal prematurity is widely accepted. While some
links have been established, others remain speculative (Table 6.12).PROPHYLACTIC AND THERAPEUTIC VACCINES
FOR ADDICTION
Candidate vaccines are in development for the prevention and
treatment of various types of addiction. The basic concept is to
induce the production of antibodies which will bind the drug and
impede its crossing the bloodebrain barrier to exert its psychoactive
effects. Several nicotine candidate vaccines have now entered
clinical trials. A cocaine candidate vaccine has also shown some
beneﬁt in a Phase IIb clinical trial. The key issue to date for both
nicotine and cocaine candidate vaccines has been to induce
Continued on next page
TABLE 6.12. EXAMPLES OF NON-INFECTIOUS DISEASES WHERE INFECTIOUS AGENTS HAVE BEEN IDENTIFIED OR
POSTULATED AS CONTRIBUTORY CAUSES
Disease Proposed infectious agent Vaccine status Causal link
Cervical cancer HPV Licensed vaccine Established
Gastric ulcer disease
Gastric cancer
Helicobacter pylori In development Established
Systemic lupus erythematosus Trypanosoma cruzi In development Speculative and indirect
(via the formation of anti-P and
antiphospholipid antibodies)
Glandular fever
Burkitt’s lymphoma
Nasopharyngeal carcinoma
Multiple sclerosis
EBV In development Established
Strong
Established
Strong
Hepatocellular carcinoma HBV
HCV
HBV e licensed vaccine
HCV e in development
Established
Strong
Kaposi’s sarcoma HHV-8 (in patients with AIDS) No candidate vaccine Strong
Foetal prematurity Bacterial vaginosis No candidate vaccine Established
Congenital mental retardation CMV In development Established
Asthma exacerbations Rhinovirus No candidate vaccine Established
Diabetes mellitus (type I) Fungal infection/mycotoxins No candidate vaccine Speculative
Alzheimer’s disease/dementia/
cognitive impairment
HSV-1
Helicobacter pylori
Picornavirus
Borna disease virus
Chlamydia pneumoniae
HSV e in development
Helicobacter pylori e in
development
Others e no candidate
vaccine
Speculative
Schizophrenia CMV
Toxoplasma gondii
HHV-6
CMV e in
development
Others e no candidate
vaccine
Speculative
Atherosclerosis Chlamydia pneumoniae No candidate vaccine Speculative
Hypertension HHV-8 No candidate vaccine Weak/unlikely
Obesity/weight gain Adenovirus-36 No candidate vaccine Speculative, possibly geographical
Rheumatoid arthritis EBV
HHV-6
EBV e in development
HHV-6 e no candidate
vaccine
Speculative
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TABLE 6.12. EXAMPLES OF NON-INFECTIOUS DISEASES WHERE INFECTIOUS AGENTS HAVE BEEN IDENTIFIED OR
POSTULATED AS CONTRIBUTORY CAUSES e CONTINUED
Disease Proposed infectious agent Vaccine status Causal link
Crohn’s disease Mycobacterium avium
subspecies paratuberculosis
No candidate vaccine Conﬂicting evidence
HPV, human papillomavirus; EBV, EpsteineBarr virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HHV, human herpesvirus; AIDS, acquired
immunodeﬁciency syndrome; CMV, cytomegalovirus; HSV, herpes simplex virus. Every effort has been made to verify the information
in this table. The information included is not meant to be exhaustive but is intended to provide an overview of the subject matter.
“It’s easy to quit smoking. I’ve done it
hundreds of times” Mark Twain
Infectious diseases cause approximately
17% of new cancers worldwide, about
1.5 million (26%) cancers in low-resource
and middle-resource countries (where
84% of the world’s population resides),
and 360,000 (7.2%) cancers in
high-resource countries (where 16% of
the world’s population resides).
VACCINES OF THE FUTURE 189high immunoglobulin (Ig)G anti-drug antibody levels, which appear
to be critical in achieving some degree of efﬁcacy. Candidate
vaccines against methamphetamine addiction are also in
early development.
PROPHYLACTIC AND THERAPEUTIC VACCINES
FOR CANCER
To date, the approach to developing prophylactic cancer vaccines
has been to target infectious diseases that cause or contribute to
the development of cancer such as HPV (cervical cancer) and HBV
(hepatocellular carcinoma). Examples of infectious diseases
associated with cancer are shown in Table 6.13. The successful
development of a nicotine vaccine would be expected to reduce
cigarette smoking-related lung cancer.
Some cancers express tissue-speciﬁc antigens that can be
targeted by the immune system. Therapeutic cancer vaccines aim
to target tumour-associated antigens (TAA) with T-cell mediated
immune responses. TAA can be related to the genetic changes that
drive the cancer (eg Ras oncogene), or inappropriate up-regulation/
expression of genes (eg carcinoembryonic antigen). With such TAA
targets, vaccines aim to maximally stimulate a cytotoxic T-cell
response and their design often includes adjuvants to enhance
antigen presentation. Tumours develop in a multistep process in the
face of the host immune response and frequently evolve to escape
immune control. Mechanisms of evasion include genetic changes
(loss of human leukocyte antigen/TAA expression) and induction
of immune regulatory systems (T-cell anergy due to the activity of
TABLE 6.13. INFECTIOUS DISEASES ASSOCIATED WITH CANCER
Pathogen Type of
organism
Associated cancer(s)
HBV Virus Hepatocellular carcinoma
HCV Virus Hepatocellular carcinoma
HPV (high-risk types) Virus Cervical cancer, vaginal cancer, vulvar cancer, oropharyngeal cancer, anal cancer,
penile cancer
EBV Virus Burkitt’s lymphoma, non-Hodgkin’s lymphoma, Hodgkin’s lymphoma,
nasopharyngeal carcinoma
HHV Virus Kaposi’s sarcoma, primary effusion lymphoma
Human T-cell lymphotropic virus 1 Virus Acute T-cell leukaemia
JC and BK polyomaviruses Virus Brain tumours
Helicobacter pylori Bacterium Stomach cancer
Schistosoma hematobium
(schistosomiasis)
Parasite Bladder cancer
Opisthorchis viverrini (liver ﬂukes) Parasite Cholangiocarcinoma
HBV, hepatitis B virus; HCV, hepatitis C virus; HPV, human papillomavirus; EBV, epsteineBarr virus; HHV, human herpesvirus 8; JC and BK, initials
of patients from whom polyomavirus isolates were obtained. Every effort has been made to verify the information in this table. The information
included is not meant to be exhaustive but is intended to provide an overview of the subject matter.
190 UNDERSTANDING MODERN VACCINESTreg cells) which limit anti-tumour immunity. The key approach for
therapeutic cancer vaccines is resetting the immune response to
deliver anti-tumour immunity that alters or destroys cancer cells and
hence eliminates or reduces the tumour. One strategy uses the
patient’s own tumour as the immunogen, thereby providing all the
potential idiotypic changes that might act as TAA, in conjunction
with antigen-presenting DCs harvested from the same patient and
activated in vitro (see Dendritic cell vaccines). There are different
types of therapeutic candidate vaccines currently undergoing
clinical trials for numerous types of cancer (Table 6.14). The
most advanced candidates currently in Phase III are described in
Chapter 4 e Vaccine adjuvants.
There has been some success in the development of therapeutic
cancer vaccines, with the FDA approval of the ﬁrst DC vaccine
TABLE 6.14. EXAMPLES OF THERAPEUTIC CANCER VACCINES IN CLINICAL TRIALS
Cancer type Vaccine approach Manufacturer/Developer
Bladder cancer Multi-epitope cancer vaccine to the MUC1
tumour-associated antigen
Vaxil Bio Therapeutics Ltd
Brain tumours Dendritic cell vaccine Samuel Oschin Comprehensive Cancer
Institute
Cervical cancer RO5217790 consists of recombinant
modiﬁed vaccinia Ankara viral vector
encoding mutated forms of human
papillomavirus type 16 genes for the viral
oncoproteins E6 and E7 and the hIL2
Roche
Melanoma DNA vaccine (tyrosinase-related protein 2)
e an immunobody adjuvant approach
ASCI, MAGE-A3/AS15
Human anti-CTLA-4 antibody (MDX-010) in
combination with a gp100 melanoma
vaccine (MDX-1379)
Scancell Ltd
GSK Biologicals
Bristol-Myers Squibb
Lung cancer Modiﬁed mRNA vaccine encoding ﬁve
antigens including NY-ESO-1
ASCI, MAGE-A3/AS15
CureVac GmbH
GSK Biologicals
Colorectal cancer Modiﬁed vaccinia Ankara encoding the
tumour antigen 5T4
Oxford BioMedica
MUC1, Mucin 1 cell surface; hIL2, human cytokine interleukin-2; ASCI, antigen-speciﬁc cancer immunotherapeutics; MAGE, melanoma-
associated antigen; CTL, cytotoxic T lymphocyte. Every effort has been made to verify the information in this table. The information included is not
meant to be exhaustive but is intended to provide an overview of the subject matter.
VACCINES OF THE FUTURE 191designed for the treatment of prostate cancer in 2010 (see Dendritic
cell vaccines). Other vaccines have been licensed in individual
countries for treatment of cancers including non-small-cell lung
cancer and melanoma.
New and more effective vaccines
for speciﬁc populations
Developing vaccines that are effective in all populations is difﬁcult
because some populations do not respond adequately to traditional
192 UNDERSTANDING MODERN VACCINESvaccine approaches. However, this presents opportunities for the
application of novel technologies and adjuvants. Some of the
considerations for vaccines designed for use in special populations
include: immunosenescence in the elderly; the poor immunological
response to traditional vaccines seen in immunocompromised
individuals (patients with HIV, transplant recipients); the crossing of
vaccine components into the foetal bloodstream when vaccines
are administered to pregnant women; and the safety and
immunogenicity concerns surrounding vaccines for neonates due
to their naïve and immature immune system.
VACCINES FOR PREGNANT WOMEN
Cell-mediated immunity is depressed in pregnant women, leaving
them at high risk of infection from pathogens, including those
harmful to the foetus. Most live, attenuated vaccines are
contraindicated during pregnancy because of the theoretical risk of
foetal infection from the vaccine. However, inactivated viral or
bacterial vaccines can be administered. Pregnant women can,
therefore, be vaccinated against some infections, including several
that pass from mother to foetus (such as hepatitis A and B), and
against infections acquired by the infant in the ﬁrst few months of life
(often from close contact with the mother). In the latter case, the
infant can be protected by transfer of maternal antibodies during
late gestation. Examples of diseases that can be prevented in
pregnant women include inﬂuenza, tetanus, diphtheria and probably
pertussis. Other diseases, such as those caused by the so-called
TORCH pathogens (toxoplasma, others including syphilis, CMV
and HSV), are not yet preventable through vaccination though
encouraging Phase II results have been presented for a vaccine to
prevent Group B streptococcus carriage in pregnant women (Hillier
et al., 2009; Smith, 2009).
The 2009 H1N1 pandemic inﬂuenza outbreak posed an increased
risk to pregnant women and vaccination was speciﬁcally
recommended in pregnant women as one of the high-risk groups.
The pandemic example has emphasised once more the
importance of protecting pregnant women against inﬂuenza.
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the beneﬁterisk proﬁle when administered to pregnant women
supports its use during pregnancy. Many public health authorities
worldwide recommend seasonal inﬂuenza vaccination in pregnant
women and this recommendation is motivated not only by the
potentially severe course of inﬂuenza during pregnancy, but also by
the need to protect vulnerable infants against inﬂuenza during their
ﬁrst months of life. Boosting RSV immunity in pregnant women
through vaccination may be another approach to protecting the
newborn against RSV infection during the most vulnerable early
months after birth.
VACCINES FOR NEONATAL INFANTS
Neonatal immunisation is a strategy to protect infants against
infections during a particularly vulnerable period. A recent study
showed that immunisation with an acellular pertussis vaccine at
birth and 1 month of age induces high IgG anti-pertussis antibody
titres by 2 months of age (Wood et al., 2010). It is hoped that this
approach may reduce death and morbidity from Bordetella
pertussis infection in the ﬁrst 3 months of life.
VACCINES FOR THE ELDERLY
The elderly respond poorly to vaccination as the immune system
becomes more senescent with increasing age and, therefore, new
vaccine technologies are needed to improve the response to
vaccination in this population. In the late 1990s, an inﬂuenza vaccine
adjuvanted with the oil-in-water emulsion,MF59, was shown to be
more effective at inducing high immune responses in the elderly
(Minutello et al., 1999). Alternative vaccine administration
techniques have also been studied in the elderly. Research showed
that in subjects 60 years of age or older, an inﬂuenza vaccine
administered with an intradermal microinjection system induced
signiﬁcantly higher antibody titres compared with IM vaccination
(Arnou et al., 2009). Subsequently, a microinjection system
inﬂuenza vaccine was licensed for use in Europe, and a high antigen
dose formulation has been licensed for the elderly in the USA.
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IMMUNOCOMPROMISED
Individuals with cancer, HIV infection or who are asplenic can be
immunocompromised as a result of their condition. Patients can also
be immunocompromised as a result of therapy, eg when receiving
an organ transplant, radiation therapy or immunosuppressive
medication. Such patients are therefore at an elevated risk of
infection from pathogens such as herpesviruses (particularly
CMV and EpsteineBarr virus), HBV, HCV, pneumocystis and
coinfections and represent a special population regarding
immunisation. Despite a likely reduction in the efﬁcacy of
vaccinations in immunocompromised individuals, immunisation
remains a frequent recommendation in the hope that at least partial
immunity will be achieved. Eliciting a response from vaccination in
immunocompromised patients may require an increase in the dose
and/or number of doses; altering the dosing interval; selecting
a different vaccine formulation; or administration via an alternative
route. Evidence in this patient population is lacking and guidelines
are often based on theoretical assumptions.
Live vaccines are generally contraindicated in immunocompromised
or immunosuppressed individuals due to the risk of an active
and symptomatic infection resulting from the vaccine itself
(non-controlled replication process). Encouragingly, vaccine
formulations with highly puriﬁed antigens and novel adjuvants or
alternative deliveries have been shown to induce more effective
immune responses than the classical inactivated vaccines in
immunocompromised hosts, including patients with end-stage renal
diseases in pre-haemodialysis and haemodialysis (see Chapter 4 e
Vaccine Adjuvants), patients with HIV and those who have received
haematological stem cell transplants.Conclusion
The future of vaccine development can build on the knowledge and
experience gained over the last 200 years, and at the same time
can take advantage of the most cutting-edge technologies and
VACCINES OF THE FUTURE 195research. New approaches to antigen selection and production,
antigen delivery, adjuvantation and vaccine administration will allow
us to target established and emerging diseases, and populations
with complex needs. Vaccination has been one of the most
successful and cost-effective health interventions ever conceived
and is now expanding further into cancer and chronic diseases. This
expansion of scope and the subsequent impact on human disease
is likely to continue into the future in currently unforeseen ways,
further increasing the importance of vaccine science and
engineering in improving human health.
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